RxDoctor Payments Data

Corinna Hansen, APRN

Family · Norfolk, NENPI 1578016838

Payments from drug & device makers

$1,729in general payments, 2019–2025

Across 110 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$253
  • Lilly USA, LLC$215
  • Novo Nordisk$212
  • Amgen$140
  • AbbVie$137
  • Astellas Pharma US Inc$134
  • plus $637 from 14 others

What the payments were for

  • Food & beverage$1,729100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,729 in reported general payments places this provider in the 80th percentile of 809 family providers in Nebraska.

See all family providers in Nebraska

Medicare billing

Part B allowed, 2024
$25,472
Medicare patients
89
Services billed
709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lamictal XrLamotrigine23$54,748
OzempicSemaglutide18$29,182
FarxigaDapagliflozin Propanediol22$20,977
KerendiaFinerenone18$19,014
Tresiba Flextouch U-200Insulin Degludec16$12,804
QuliptaAtogepant11$11,530
JanuviaSitagliptin Phosphate12$6,323
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$4,349
SymbicortBudesonide/Formoterol Fumarate11$2,443
Dexlansoprazole DrDexlansoprazole12$1,923
Potassium Chloride54$1,845
Celecoxib23$1,350
Gabapentin39$819
Pantoprazole Sodium33$774
Montelukast Sodium36$752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$212$29,18218 claims
AstraZenecaFarxiga, Symbicort$106$23,42033 claims
BayerKerendia$67$19,01418 claims
AbbVieQulipta$137$11,53011 claims
MerckJanuvia$128$6,32312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 809 family providers in Nebraska.

Other family in Norfolk

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →